Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eckert & Ziegler SECHIX:EUZD 94 EV-to-EBIT is 10.13 as of Aug. 12, 2026, which is 34% below its 10-year median of 15.38. GuruFocus rates CHIX:EUZD with a GF Score™ of 94/100 and a GF Value™ of €17.76. Among 473 Medical Devices & Instruments companies, Eckert & Ziegler SE ranks better than 77.38% on this metric.
The historical rank and industry rank for Eckert & Ziegler SE's EV-to-EBIT or its related term are showing as below:
CHIX:EUZd'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.2 Med: 15.38 Max: 58.07
Current: 10.13
During the past 13 years, the highest EV-to-EBIT of Eckert & Ziegler SE was 58.07. The lowest was 5.20. And the median was 15.38.
CHIX:EUZd's EV-to-EBIT is ranked better than 77.38% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 19.01
vs CHIX:EUZd: 10.13
Eckert & Ziegler SE (CHIX:EUZd) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Eckert & Ziegler SE's Enterprise Value for the quarter that ended in Mar. 2026 was €842.4 Mil.
Eckert & Ziegler SE's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €78.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eckert & Ziegler SE EV-to-EBIT Related Terms
Eckert & Ziegler SE EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Eckert & Ziegler SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's EV-to-EBIT falls into.
Eckert & Ziegler SE's current Enterprise Value is €793.0 Mil.
Eckert & Ziegler SE's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €78.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eckert & Ziegler SE (CHIX:EUZD) has a EV-to-EBIT of 10.13 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eckert & Ziegler SE and its competitors. This is 34% below median its historical median of 15.38. Over the past decade, Eckert & Ziegler SE's EV-to-EBIT has ranged from 5.20 to 58.07. According to the industry distribution chart, Eckert & Ziegler SE ranks #107 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 22.6%.
Is Eckert & Ziegler SE's EV-to-EBIT too high?
Eckert & Ziegler SE's current EV-to-EBIT of 10.13 is 34% below median its 10-year median of 15.38. Over the past 10 years, this metric has ranged from a low of 5.20 to a high of 58.07. The Medical Devices & Instruments industry median EV-to-EBIT is 19.01. Eckert & Ziegler SE's value of 10.13 is 46.7% below this industry median. Based on the distribution chart, Eckert & Ziegler SE ranks #107 out of 473 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Eckert & Ziegler SE has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #107 out of 473 companies for EV-to-EBIT. This places Eckert & Ziegler SE in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.01. Eckert & Ziegler SE's value of 10.13 is 46.7% below this benchmark. Historically, Eckert & Ziegler SE's own EV-to-EBIT has ranged from 5.20 to 58.07 over the past decade. While the company's 10-year median is 15.38 vs. the industry median of 19.01, Eckert & Ziegler SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.01, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current EV-to-EBIT of 10.13 is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current EV-to-EBIT is 10.13, which is 34% below median its own 10-year median of 15.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Eckert & Ziegler SE (CHIX:EUZD) has a current EV-to-EBIT of 10.13. The stock's GF Value™ is €17.76, compared to a current price of €15.19 — trading 14.5% below its estimated fair value. The current EV-to-EBIT is 10.13, which is 34% below median its 10-year median of 15.38 and 46.7% below the Medical Devices & Instruments industry median of 19.01. Eckert & Ziegler SE's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Eckert & Ziegler SE (CHIX:EUZD), the current EV-to-EBIT is 10.13 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (CHIX:EUZD) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.19 is trading 14.5% below its estimated GF Value™ of €17.76.
Key valuation signals for CHIX:EUZD:
EV-to-EBIT: 10.13 (34% below median its 10-year median of 15.38)
GF Value™: €17.76 vs. price of €15.19 (14.5% below fair value)
Industry Position: 46.7% below the Medical Devices & Instruments median (#107 of 473)
No single metric tells the full story. See the CHIX:EUZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
94GF Score
Get the complete analysis for CHIX:EUZD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:EUZD has been successfully added to your 
